- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07950462
A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of QLS7402 Injection Administered Subcutaneously in Adult Participants With Overweight or Obesity
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity
연구 개요
상세 설명
This is a first-in-human (FIH), randomized, double-blind, placebo-controlled Phase 1 clinical study of QLS7402 injection, which consists of a single ascending dose (SAD) study in adult participants with overweight or obesity. The study is designed to evaluate the safety, tolerability, PK, and PD of QLS7402 following single subcutaneous administration. In accordance with the dose escalation principle, dose escalation will proceed sequentially from the starting dose to higher dose levels. An individual trial participant will receive only one dose level as a single dose. This study is designed with 5 prespecified escalating dose groups.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Qing wen, Master of Medicine
- 전화번호: +86-13370551767
- 이메일: wenq0619@126.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 1)Willing to participate in this study and provide written informed consent prior to any study-specific procedures; able to understand the study procedures, methods, requirements, and restrictions; and willing to comply with the protocol and complete the study.
- 2) Male and female adults aged between 18 and 55 years, inclusive, at the time of informed consent.
- 3) 27.0 kg/m²≤BMI<35.0 kg/m² at screening.
- 4) Body weight has remained stable for at least 3 months prior to screening(defined as a weight change within ±5%, participant self-reported information is acceptable).
Exclusion Criteria:
- 1) Evidence or history or presence of major diseases, including but not limited to disorders involving the cardiovascular, endocrine (except for primary obesity and mild to moderate hepatic steatosis with normal hepatic function), psychiatric, neurological, gastrointestinal, respiratory, hematological, immunological, urogenital, renal, hepatic, pulmonary, or dermatological systems, or any other condition that, in the judgment of the Investigator, makes the participant unsuitable for this study.
- 2) History of endocrine disorders that may significantly affect body weight (e.g., Cushing's syndrome, hypothalamic obesity, hypothyroidism, or hyperthyroidism), or history of medication-induced obesity, monogenic obesity, or hereditary obesity syndromes.
- 3) History of malignancy.
- 4) Skin conditions and/or tattoos that may interfere with the evaluation of injection site reactions, or abdominal scarring (e.g., due to surgery or burns) that may affect subcutaneous administration; intolerance to subcutaneous injection which, in the investigator's opinion, may preclude study drug administration or local tolerability assessment.
- 5) Difficult venous access (e.g., history of needle phobia or blood phobia), or poor venous conditions that, in the judgment of the Investigator, render the participant unsuitable for enrollment.
- 6) History of or planned any form of bariatric surgery or device-based treatment for obesity during the study period; severe trauma or major surgery within 6 months prior to screening; or planned surgery during the study period.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: QLS7402
QLS7402 Injection |
QLS7402 Injection |
|
위약 비교기: Placebo
Placebo Control |
Placebo Control |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs)
기간: 169 days
|
169 days
|
|
Number of participants with treatment-related adverse events (TRAEs)
기간: 169 days
|
169 days
|
|
Number of participants with serious adverse events (SAEs)
기간: 169 days
|
169 days
|
|
Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory tests
기간: 169 days
|
169 days
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
The change from baseline in Maximum Plasma Concentration (Cmax)
기간: 3 days
|
3 days
|
|
The change from baseline in Activin E levels
기간: 169 days
|
169 days
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- QLS7402-101
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .